IMUNON CEO Issues Letter to Shareholders
Reviews 2022 accomplishments; sets forth 2023 milestones and long-term vision LAWRENCEVILLE, N.J. , March 01, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) , a clinical-stage biotechnology company, today announced that Dr. Corinne Le Goff , the company’s president and chief executive
March 1, 2023
IMUNON Receives $1.6 Million from Sale of its New Jersey Net Operating Losses
Non-dilutive funding strengthens balance sheet and extends current operating runway into 2025 The sale of an additional $1.8 million of unused New Jersey NOLs expected in 2023 LAWRENCEVILLE, NJ , Jan. 12, 2023 (GLOBE NEWSWIRE) -- I MUNON , Inc.   (NASDAQ: IMNN ) , a clinical-stage drug development
January 12, 2023